Post on 19-Jun-2020
transcript
© Bluechiip Ltd | All Rights Reserved
© Bluechiip Ltd | All Rights Reserved
Unique patented MEMS technology combining secure wireless tracking with integrated temperature sensing for extreme environments
Bluechiip LtdMar 2017
© Bluechiip Ltd | All Rights Reserved 2
DisclaimerMaterial used in this presentation is a summary of available information, and while given in good faith, isprofessional opinion only. Any investor in Bluechiip Limited (BCT) should refer to all BCT ASX releases andstatutory reports before considering investment in the company.
Certain information may have been derived from third parties and though BCT has no reason to believe thatit is not accurate, reliable or complete, it has not been independently audited or verified by BCT.
Any forward-looking statements in this presentation involve subjective judgment and analysis and are subjectto uncertainties, risks and contingencies, many of which are outside control of, and maybe unknown to, BCT.Neither BCT, nor its officers, employees and advisors make or give any representation, warranty or guaranteein relation to this presentation.
BCT reserves right to update, amend or supplement information in this presentation at any time in itsabsolute discretion without incurring any obligation to do so.
Bluechiip Sample TrackingIntroduction
© Bluechiip Ltd | All Rights Reserved 4
Our Team
Introduction
Board
Corporate
Iain Kirkwood Andrew McLellan Michael Ohanessian
Chairman
Experienced investor and non-executive director (listed and unlisted). Iain has considerable practical and operational experience gained from a successful financial career spanning 35 years including in resources, manufacturing and latterly healthcare in Australia, Britain and the USA. Iain has been a major shareholder in Bluechiip for over 5 years.
Managing Director
Experienced in innovation and commercialisation combined with significant technical and operational background. Andrew has held senior positions including as VP of Business Development in North America and Director at Leica Microsystems (previously Vision BioSystems a division of the publicly listed Vision Systems), and as CEO of the Advanced Manufacturing Co-operative Research Centre (AMCRC)
Non-executive Director
CEO and Managing Director of Praemium Ltd, Michael brings executive experience in technology-related businesses. Previously CEO of Vision BioSystems Michael led the technology commercialisation into global markets before its parent Vision Systems was acquired by US based Danaher Corp. Michael brings a mixture of operational, strategic and leadership capabilities to his role at Bluechiip.
Team
Scott Turner Dr Ian Johnston Irvin Teoh David White & Hugh Douglas
Engineering Manager
Product Engineering Manager, MEMS (EU)
Finance Manager Business Development North America (US)
Oscar Val
Technical Sales and Marketing Manager
4
Corporate overview
CorporateIntroduction
© Bluechiip Ltd | All Rights Reserved
Top Shareholders
Summary (As at 31 Jan 2017)
Share Price
Pulitano Family 8.82%
Dr. Stephen Woodford 8.37%
Chairman & Entities 7.32%
Planet Innovation 5.02%
Top 20 Shareholders 51.48%
Founder 1.57%
Number of Shareholders 708 Shares on Issue 271,810,092
Share Price 4.0c Market Cap. $10.87m
Cash Balance (31 Dec 2016) $1.092m
0
2
4
6
8
10
12
14
16
0c
1c
2c
3c
4c
5c
6c
7c
8c
Vo
lum
e (
mill
ion
)
Shar
e P
rice
(ce
nt)
BluechiipSample tracking for extreme environments using MEMS sensors
• Unique Micro-Electro Mechanical Systems (MEMS) micro
device, superior to labels, barcodes and RFID
• Provides ID extremely difficult to copy
• Operates reliably between -196ᵒC & 100ᵒC
• Instant sample temperature sensing
• Reads in under 0.3 second, even through frost
• Sterilisation resistant including Gamma radiation
• Can be moulded into any plastic
• Reduces human error
• Increases productivity
© Bluechiip Ltd | All Rights Reserved 5
Our Product : Chip + Reader + Software
OverviewIntroduction
6© Bluechiip Ltd | All Rights Reserved
Alternative technologies
Our SolutionBiobanking Today
Gamma Resistant
Cryo safeSurvives extreme temps
Non visual IDReads through frost
On-board sensorTemperature sensing
Reduced human error
Productivity improvements
HUMAN READABLE BARCODES RFID BLUECHIIP
© Bluechiip Ltd | All Rights Reserved
Primary Applications
7
• Sample tracking and identification• Biopreservation• Life sciences• Research • Pharmaceuticals• Personalised Therapies
8© Bluechiip Ltd | All Rights Reserved
Primary Market Opportunity
MarketStrategy
Cryogenic(-196C°)
Non-cryogenic (-80C°)
Total biobanking: 2B samples in storage300M new samples per year
Sources: Visual Fuse and MarketsandMarkets 2014
Global Biopreservation Market Greater than $2B in 2015
© Bluechiip Ltd | All Rights Reserved 9
SegmentsBiobanking Today
IVF Sperm/EggsBloodTissue StemCellBiologics
Biosample tracking technology is not keeping up with the increasing value of biosamples
© Bluechiip Ltd | All Rights Reserved 10
Biopreservation Trends300+ million biosamples per annum, 2+ billion in storage
NeedsBiobanking Today
High volume processing
Dual labelling
Criticality of temperature on quality
Increasing demand for Cryogenic storage
Icon here
Icon here
Icon here
Icon here
Other addressable markets
Adjacent MarketsStrategy
Cold Chain LogisticPharmaceuticals
Cold Chain Logistics Food
Industrial and Manufacturing
Security & Defence
Icon here
Icon here
Icon here
Icon here
Item level temperature tracking of pharmaceuticals through-out the cold chain cycle.
Item level temperature tracking of frozen and temperature sensitive food stuffs through-out the cold chain cycle.
High temperature tracking, structural health monitoring, tracking of tools and parts that are exposed to ionizing radiation or gamma radiation including sterilised medical devices, disposables and some food products.
Anti counterfeiting fashion, food and high value commercial items. Cloning a bluechiip® tag is extremely difficult. tracking of tools and parts that are exposed to ionizing radiation, security and defense.
© Bluechiip Ltd | All Rights Reserved 11
© Bluechiip Ltd | All Rights Reserved
Strategic Progress and Sales Pipeline
12
13© Bluechiip Ltd | All Rights Reserved
Solutions for OEM Partners
ProductsTechnology Introduction
High Value Target Markets
Strategy
© Bluechiip Ltd | All Rights Reserved 14
1,800,000
2,500,000
3,000,000
3,700,000
15,000,000
7,500,000
IVF PROTEINCRYSTALLOGRAPHY
REGENERATIVEMEDICINE OTHERCRYOANDTRANSPORT
GENERALBIOBANKING GENERALBIOBANKING-NEXTGENERATIONCHIPS
NUMBER
OFUNITS
Annualconsumables(Chiips) Storedconsumables
Bluechiip Opportunity(USD) $20m+ $2.5M+ $30M+ $30M+ $200M+
OEM PIPELINE CLIENTS
Agreement Dec 2015Revenue Mar 2016Displayed July ‘16Target Launch 2017
Executed agreement Evaluation in progressValidation Customers
Executed agreement Evaluation in progressValidation customers
Evaluation agreements & developer kits in progress
Developer kits sold with multiple vendors & validation customers
R&D Development.High value over temperature sensors
30
0 M
2 B
30
0 M
$1.5B+
33
M
Bluechiipopportunity ($US)
Market Opportunities
• Partner pipeline grown to over 30 opportunities
• Genea Biomedx – OEM Supply Agreement Executed
• Planet Innovation - OEM Supply Agreement and Investment
• 2016: 9 Developer & Starter Kits sold with sales accelerating
• Mar : Autism CRC – End user. Ongoing consumables• Jun: US Cryogenics consumables manufacturer
• Australian researcher organisation• Aug: Centre for Disease Control China (CDC China)• Sep: US Auto ID and Data Capture Company• Nov: Kit sale to CDC China
• 2 Kit sales to SIAD in EU –biobank solution provider• Kit sale to Denmark University – OEM validator
• Dec: Kit sale to The Netherlands
2016 Pipeline and ResultsDramatic increase
Pipeline ProgressStrategy
© Bluechiip Ltd | All Rights Reserved 15
Engagement (Non-Disclosure
Agreement)
Sale of developer/trial kit,
evaluation agreement
Development & Supply agreement
Demonstration in market
Commercial product
“Bluechiip Inside”
OEM
End User
Validation Validation
16© Bluechiip Ltd | All Rights Reserved
Genea Biomedx License & Supply Agreement
PartneringStrategy
• Dec 2015 Genea Biomedx – OEM Supply Agreement Executed
• Incorporate Bluechiips technology to Genea’s range of Assisted
Reproductive Technologies instruments
• Feb 2016 Successfully Completed concept due diligence
• July 2016 Demonstration in Market at (ESHRE) trade show Europe
• 2017 Pilot & Launch Commercial Product
17© Bluechiip Ltd | All Rights Reserved
Bluechiip IVF Transport CoolerActive ID and Temperature Recording in Liquid Nitrogen -196o C
PartneringStrategy
https://www.youtube.com/watch?v=8BbZZgXnKjY
18
Planet Innovation OEM Partnership
© Bluechiip Ltd | All Rights Reserved
PartneringStrategy
• OEM Supply and Master Services Agreement Executed in September ‘16
• Planet Innovation direct investment with a significant shareholding
• Actively pursuing partnerships to incorporate Bluechiip technology into Planet Innovation’s Partners Products
19© Bluechiip Ltd | All Rights Reserved
Product PipelineChiips
ProductsStrategy
Market feedback. Independent SurveySample Storage Quality & Identification Tracking Trends 2016
Market feedbackStrategy
© Bluechiip Ltd | All Rights Reserved 20
• Largest markets US (47%) and Europe (27%)
• Freeze/Thaw cycles regarded as the main obstacle to sample quality
• Stored samples exposed to at least 1 significant temperature change per day
• Overtemperature regarded as the most valuable feature of all
• Estimated cost to replace a poor quality sample is USD 51-100. With some samples
well in excess of thousands of dollars.
• For MEMS ID fitted 2ml vials market potential is around USD $40M a year (2ml vials account for only a portion of the total vial storage market)
Source: Independent market research report, Nov 2016, HTStec
21© Bluechiip Ltd | All Rights Reserved
Product PipelineReaders
ProductsStrategy
Bluechiips• Government co-funded projects with Melbourne and Swinburne
Universities to adapt to multiple formats
• Overtemperature chip, 2nd stage funding awarded & Patent Application submitted
Over
T°C
22© Bluechiip Ltd | All Rights Reserved
Bluechiip Blue TrayActive ID and Temperature Recording in Transit
ProductsStrategy
https://www.youtube.com/watch?v=8H350vEC9GQ
1. Well protected and expanding differentiated IP portfolio
2. Large growing target market with very large adjacent market opportunities
3. Dramatically increasing partner pipeline with well advanced product development
4. Partner opportunity conversion with 2 executed licence and supply agreements
5. Initial repeat revenues with licence, service and product sales expected to grow in 2017
on partner’s product launch
Summary
Pipeline ProgressStrategy
© Bluechiip Ltd | All Rights Reserved 23
Need hi-res image
Contact
© Bluechiip Ltd | All Rights Reserved
© Bluechiip Ltd | All Rights Reserved
Andrew McLellan, Managing Director & CEOTel: +61 (0)3 9763 9763Mob: +61 (0)457 823 470Email: andrew.mclellan@bluechiip.comwww.bluechiip.com